EMFAT
UTHR icon

Emerald Mutual Fund Advisers Trust’s United Therapeutics UTHR Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.97M Buy
8,384
+784
+10% +$390K 0.24% 113
2025
Q4 		$3.7M Buy
7,600
+2,126
+39% +$990K 0.18% 112
2025
Q3 		$2.29M Buy
5,474
+2,894
+112% +$973K 0.12% 126
2025
Q2 		$741K Buy
2,580
+33
+1% +$9.86K 0.05% 150
2025
Q1 		$785K Sell
2,547
-155
-6% -$53.1K 0.06% 142
2024
Q4 		$953K Buy
2,702
+2,391
+769% +$879K 0.06% 139
2024
Q3 		$111K Buy
+311
New +$105K 0.01% 218
2023
Q3 		– Sell
-501
Closed -$111K – 254
2023
Q2 		$111K Sell
501
-55,402
-99% -$12.3M 0.01% 227
2023
Q1 		$12.5M Sell
55,903
-11,935
-18% -$2.94M 0.74% 60
2022
Q4 		$18.9M Sell
67,838
-34,979
-34% -$8.83M 1.17% 30
2022
Q3 		$21.5M Sell
102,817
-30,846
-23% -$6.9M 1.36% 14
2022
Q2 		$31.5M Sell
133,663
-40,277
-23% -$8.19M 1.83% 4
2022
Q1 		$31.2M Sell
173,940
-16,083
-8% -$3.06M 1.38% 18
2021
Q4 		$41.1M Buy
190,023
+5,940
+3% +$1.17M 1.45% 13
2021
Q3 		$34M Sell
184,083
-206
-0.1% -$40.6K 1.18% 26
2021
Q2 		$33.1M Sell
184,289
-2,197
-1% -$418K 1.08% 28
2021
Q1 		$31.2M Buy
186,486
+517
+0.3% +$86.2K 1.04% 24
2020
Q4 		$28.2M Buy
185,969
+11,923
+7% +$1.56M 0.98% 32
2020
Q3 		$17.6M Buy
174,046
+209
+0.1% +$22.9K 0.78% 52
2020
Q2 		$21M Buy
173,837
+66,084
+61% +$7.44M 0.99% 33
2020
Q1 		$10.2M Buy
+107,753
New +$10.2M 0.64% 56

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's UTHR Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust increased its United Therapeutics (UTHR) stake by 10% in Q1 2026, buying an estimated $390K and bringing the position to 8,384 shares worth $4.97M. The position accounts for 0.24% of the portfolio, ranked #113.

Emerald Mutual Fund Advisers Trust first reported a position in UTHR in Q1 2020 and has held it in 21 quarters since. The position peaked at $41.1M in Q4 2021. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Emerald Mutual Fund Advisers Trust held 8,384 shares of United Therapeutics worth $4.97M as of Q1 2026.
  • Emerald Mutual Fund Advisers Trust bought 784 United Therapeutics shares in Q1 2026, an estimated $390K.
  • United Therapeutics made up 0.24% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #113 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in United Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Emerald Mutual Fund Advisers Trust's United Therapeutics position peaked at $41.1M in Q4 2021.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.